Gyre Therapeutics Inc Quick Ratio (GYRE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gyre Therapeutics Inc   (NASDAQ: GYRE)

Gyre Therapeutics Inc 's Quick Ratio

GYRE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Gyre Therapeutics Inc 's Cash & cash equivalent grew by 73.24 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Gyre Therapeutics Inc 's Quick Ratio to 4.12, Quick Ratio remained below Gyre Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 201 other companies have achieved higher Quick Ratio than Gyre Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 793, from total ranking in the first quarter 2026 at 1007.

Explain Quick Ratio?
How much Cash & cash equivalents GYRE´s has?
What are GYRE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GYRE Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 23.86 % 4.2 % 111.84 % 8.13 % 8.64 %
Y / Y Cash & cash equivalent Change 58.72 % 66.63 % 166.05 % 139.32 % 116.59 %
Quick Ratio MRQ 4.12 2.52 4.47 3.77 3.21
GYRE's Total Ranking # 793 # 1007 # 606 # 625 # 690
Seq. Current Liabilities Change 5.91 % -52.14 % 159.8 % -5.95 % -10.91 %
Seq. Cash & cash equivalent Change 73.24 % -73.02 % 207.47 % 10.46 % 81.88 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 202
Healthcare Sector # 335
Overall Market # 793


Quick Ratio Statistics
High Average Low
60.73 10.18 1.18
(Jun 30 2015)   (Mar 31 2023)




Financial Statements
Gyre Therapeutics Inc 's Current Liabilities $ 21 Millions Visit GYRE's Balance sheet
Gyre Therapeutics Inc 's Cash & cash equivalent $ 86 Millions Visit GYRE's Balance sheet
Source of GYRE's Sales Visit GYRE's Sales by Geography


Cumulative Gyre Therapeutics Inc 's Quick Ratio

GYRE's Quick Ratio for the trailling 12 Months

GYRE Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 39.71 % 36.58 % 34.45 % 4.38 % 26.58 %
Y / Y Cash & cash equivalent TTM Growth 113.03 % 133.38 % 109.59 % 42.14 % 40.21 %
Quick Ratio TTM 3.89 3.71 3.53 3 2.55
Total Ranking TTM # 3825 # 3688 # 2245 # 2832 # 2945
Seq. Current Liabilities TTM Growth 4.3 % 0.86 % 30.59 % 1.71 % 1.96 %
Seq. Cash & cash equivalent TTM Growth 9.15 % 6.05 % 53.92 % 19.56 % 19.58 %

Quick ratio ranking by company, industry and sector >> Back to GYRE Financial Strength Comparisons >> Go to Compare GYRE Quick Ratio to its Competitors

On the trailing twelve months basis GYRE Cash & cash equivalent soared by 58.72 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Gyre Therapeutics Inc 's Quick Ratio to 3.89, Quick Ratio remained below GYRE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Gyre Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3688 to 3825.

Explain Quick Ratio?
How much Cash & cash equivalents GYRE´s has?
What are GYRE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 882
Within the Market # 3825


trailing twelve months Quick Ratio Statistics
High Average Low
17.87 4.02 0.85
(Dec 31 2018)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions
Entrada Therapeutics Inc   10.44 $ 223.112  Millions$ 21.371  Millions
Vera Therapeutics Inc   10.33 $ 499.161  Millions$ 48.321  Millions
Ideaya Biosciences Inc   10.03 $ 828.955  Millions$ 82.677  Millions
Gri Bio Inc   9.95 $ 10.947  Millions$ 1.100  Millions
Renovorx Inc   9.86 $ 18.579  Millions$ 1.884  Millions
Savara Inc   9.83 $ 173.034  Millions$ 17.599  Millions
Bullfrog Ai Holdings Inc   9.79 $ 6.918  Millions$ 0.707  Millions
Enveric Biosciences Inc   9.63 $ 8.296  Millions$ 0.861  Millions
Pliant Therapeutics Inc   9.62 $ 158.500  Millions$ 16.484  Millions
Rezolute Inc   9.44 $ 107.801  Millions$ 11.418  Millions
Crescent Biopharma Inc   9.26 $ 171.593  Millions$ 18.537  Millions
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions
Synlogic Inc   9.03 $ 13.200  Millions$ 1.461  Millions
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions

Date modified: 2026-08-14T20:17:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.